HRP20171597T1 - Modulatori cxcr7-receptora - Google Patents

Modulatori cxcr7-receptora Download PDF

Info

Publication number
HRP20171597T1
HRP20171597T1 HRP20171597TT HRP20171597T HRP20171597T1 HR P20171597 T1 HRP20171597 T1 HR P20171597T1 HR P20171597T T HRP20171597T T HR P20171597TT HR P20171597 T HRP20171597 T HR P20171597T HR P20171597 T1 HRP20171597 T1 HR P20171597T1
Authority
HR
Croatia
Prior art keywords
ethyl
tetrahydro
isoquinolin
acetamide
benzyl
Prior art date
Application number
HRP20171597TT
Other languages
English (en)
Croatian (hr)
Inventor
Heinz Fretz
Philippe Guerry
Thierry Kimmerlin
Francois LEHEMBRE
Julien Pothier
Hervé SIENDT
Anja Valdenaire
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of HRP20171597T1 publication Critical patent/HRP20171597T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
HRP20171597TT 2013-05-30 2014-05-28 Modulatori cxcr7-receptora HRP20171597T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
EP14730591.6A EP3004082B1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators
PCT/IB2014/061774 WO2014191929A1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Publications (1)

Publication Number Publication Date
HRP20171597T1 true HRP20171597T1 (hr) 2017-12-01

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171597TT HRP20171597T1 (hr) 2013-05-30 2014-05-28 Modulatori cxcr7-receptora

Country Status (30)

Country Link
US (1) US9920010B2 (https=)
EP (1) EP3004082B1 (https=)
JP (1) JP6393749B2 (https=)
KR (1) KR102302580B1 (https=)
CN (1) CN105263924B (https=)
AR (1) AR096490A1 (https=)
AU (1) AU2014272718B2 (https=)
BR (1) BR112015030095B1 (https=)
CA (1) CA2912133C (https=)
CL (1) CL2015003470A1 (https=)
CY (1) CY1119537T1 (https=)
DK (1) DK3004082T3 (https=)
EA (1) EA028604B1 (https=)
ES (1) ES2645470T3 (https=)
HR (1) HRP20171597T1 (https=)
HU (1) HUE036649T2 (https=)
IL (1) IL242782B (https=)
LT (1) LT3004082T (https=)
MA (1) MA38679B1 (https=)
MX (1) MX364104B (https=)
MY (1) MY173564A (https=)
NO (1) NO3004082T3 (https=)
PH (1) PH12015502632A1 (https=)
PL (1) PL3004082T3 (https=)
PT (1) PT3004082T (https=)
SG (1) SG11201509057UA (https=)
SI (1) SI3004082T1 (https=)
TW (1) TWI640510B (https=)
UA (1) UA118562C2 (https=)
WO (1) WO2014191929A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
ES2732437T3 (es) 2014-12-01 2019-11-22 Idorsia Pharmaceuticals Ltd Moduladores del receptor de CXCR7
WO2017070431A1 (en) * 2015-10-23 2017-04-27 James Merritt Use of ccr1 antagonists as a treatment for tumors of the central nervous system
HRP20230313T1 (hr) * 2016-07-28 2023-05-12 Idorsia Pharmaceuticals Ltd Modulatori receptora cxcr7 piperidina
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
WO2002046164A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
ATE427933T1 (de) * 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
DE602006018057D1 (de) * 2005-11-10 2010-12-16 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
ES2732437T3 (es) 2014-12-01 2019-11-22 Idorsia Pharmaceuticals Ltd Moduladores del receptor de CXCR7

Also Published As

Publication number Publication date
BR112015030095A2 (pt) 2022-07-12
UA118562C2 (uk) 2019-02-11
PL3004082T3 (pl) 2018-01-31
CA2912133A1 (en) 2014-12-04
US20160107997A1 (en) 2016-04-21
KR20160013197A (ko) 2016-02-03
AU2014272718A1 (en) 2016-01-21
EP3004082A1 (en) 2016-04-13
SG11201509057UA (en) 2015-12-30
CA2912133C (en) 2021-06-22
PH12015502632B1 (en) 2016-03-07
CN105263924B (zh) 2018-10-19
IL242782B (en) 2019-06-30
PT3004082T (pt) 2017-11-13
HK1223353A1 (en) 2017-07-28
TWI640510B (zh) 2018-11-11
US9920010B2 (en) 2018-03-20
AR096490A1 (es) 2016-01-13
NZ715530A (en) 2020-12-18
AU2014272718B2 (en) 2018-06-28
ES2645470T3 (es) 2017-12-05
EA028604B1 (ru) 2017-12-29
HUE036649T2 (hu) 2018-07-30
MY173564A (en) 2020-02-04
WO2014191929A1 (en) 2014-12-04
JP6393749B2 (ja) 2018-09-19
MA38679A1 (fr) 2018-07-31
DK3004082T3 (en) 2017-10-02
IL242782A0 (en) 2016-02-01
KR102302580B1 (ko) 2021-09-15
CL2015003470A1 (es) 2016-06-17
EA201501163A1 (ru) 2016-06-30
SI3004082T1 (sl) 2017-11-30
JP2016520120A (ja) 2016-07-11
CN105263924A (zh) 2016-01-20
CY1119537T1 (el) 2018-03-07
MA38679B1 (fr) 2019-12-31
BR112015030095B1 (pt) 2023-02-28
LT3004082T (lt) 2017-10-25
MX364104B (es) 2019-04-12
NO3004082T3 (https=) 2017-12-30
PH12015502632A1 (en) 2016-03-07
TW201529557A (zh) 2015-08-01
MX2015016429A (es) 2016-03-01
EP3004082B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
HRP20171597T1 (hr) Modulatori cxcr7-receptora
JP2016520120A5 (https=)
US10195213B2 (en) Chemical entities that kill senescent cells for use in treating age-related disease
ES2660317T3 (es) Combinación de fármacos
RU2165760C2 (ru) Применение антагонистов серотонина (5нт3) для лечения фибромиалгии
RU2395506C2 (ru) Антагонисты рецептора хемокина
US7501405B2 (en) Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2006522746A5 (https=)
Pal et al. Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management
US20080108598A1 (en) Pharmaceutical use of substituted amides
WO2004089470A2 (en) New amide derivatives and pharmaceutical use thereof
RU2006142331A (ru) Комбинации, содержащие антимускариновые агенты и ингибиторы pde4
HRP20230294T1 (hr) Modulatori tmem16a
CN101674820A (zh) 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标记的方法
JP2006522750A5 (https=)
JP2007533686A5 (https=)
US20110178080A1 (en) Melanocortin Receptor-Specific Spiro-Piperidine Compounds
RU2012145298A (ru) Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний
CN1370069A (zh) 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂
KR20210062044A (ko) 퀴누클리딘-3-온 유도체와 암 치료에서 이의 용도
JP7472143B2 (ja) イオンチャネル阻害化合物を使用して過敏性咳またはかゆみを治療する方法
WO2001095902A1 (en) A composition comprising a combination of receptor agonists and antagonists
WO2010065799A2 (en) Amine substituted piperidine melanocortin receptor-specific compounds
CL2025001713A1 (es) Sal maleato de un antagonista del receptor de melanocortina subtipo 2 cristalino (mc2r).
RU2013136906A (ru) Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение